TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Substitutes 20
Rivalry 21
LEADING COMPANIES 22
Bayer AG 22
Johnson & Johnson 28
Boehringer Ingelheim GmbH 33
MARKET DISTRIBUTION 37
MARKET FORECASTS 38
Market value forecast 38
MACROECONOMIC INDICATORS 39
APPENDIX 41
Methodology 41
Industry associations 42
Related Datamonitor research 42
Disclaimer 44
ABOUT DATAMONITOR 45
Premium Reports 45
Summary Reports 45
Datamonitor consulting 45
LIST OF TABLES
Table 1: Mexico OTC pharmaceuticals market value: $ million, 2005–09 10
Table 2: Mexico OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Table 3: Mexico OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Table 4: Mexico OTC pharmaceuticals market share: % share, by value, 2009 13
Table 5: Bayer AG: key facts 22
Table 6: Bayer AG: key financials ($) 25
Table 7: Bayer AG: key financials (€) 25
Table 8: Bayer AG: key financial ratios 26
Table 9: Johnson & Johnson: key facts 28
Table 10: Johnson & Johnson: key financials ($) 30
Table 11: Johnson & Johnson: key financial ratios 31
Table 12: Boehringer Ingelheim GmbH: key facts 33
Table 13: Boehringer Ingelheim GmbH: key financials ($) 35
Table 14: Boehringer Ingelheim GmbH: key financials (€) 35
Table 15: Boehringer Ingelheim GmbH: key financial ratios 35
Table 16: Mexico OTC pharmaceuticals market distribution: % share, by value, 2009 37
Table 17: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 38
Table 18: Mexico size of population (million), 2005–09 39
Table 19: Mexico gdp (constant 2000 prices, $ billion), 2005–09 39
Table 20: Mexico gdp (current prices, $ billion), 2005–09 39
Table 21: Mexico inflation, 2005–09 40
Table 22: Mexico consumer price index (absolute), 2005–09 40
Table 23: Mexico exchange rate, 2005–09 40
LIST OF FIGURES
Figure 1: Mexico OTC pharmaceuticals market value: $ million, 2005–09 10
Figure 2: Mexico OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Figure 3: Mexico OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Figure 4: Mexico OTC pharmaceuticals market share: % share, by value, 2009 13
Figure 5: Forces driving competition in the OTC pharmaceuticals market in Mexico, 2009 14
Figure 6: Drivers of buyer power in the OTC pharmaceuticals market in Mexico, 2009 16
Figure 7: Drivers of supplier power in the OTC pharmaceuticals market in Mexico, 2009 17
Figure 8: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Mexico, 2009 18
Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Mexico, 2009 20
Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Mexico, 2009 21
Figure 11: Bayer AG: revenues & profitability 26
Figure 12: Bayer AG: assets & liabilities 27
Figure 13: Johnson & Johnson: revenues & profitability 31
Figure 14: Johnson & Johnson: assets & liabilities 32
Figure 15: Boehringer Ingelheim GmbH: revenues & profitability 36
Figure 16: Boehringer Ingelheim GmbH: assets & liabilities 36
Figure 17: Mexico OTC pharmaceuticals market distribution: % share, by value, 2009 37
Figure 18: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 38
[Fade out table of contents]
